Expertise in
14
conditions

Bruno J. Fautrel

Paris, FR 
Expertise in
14
conditions
Paris, FR 

Overview

Bruno Fautrel practices practicing medicine in Paris, France.

Mr. Fautrel is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Adult Still's Disease, and Axial Spondyloarthritis (AxSpA).

He is actively involved in clinical research, co-authoring 327 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Paris, France
Other Locations
France
Creteil, France
Toulouse, France
Pierre-la-treiche, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Combination of Baricitinib and Anti-TNF vs. Baricitinib in Patients With Rheumatoid Arthritis: a Randomized Controlled Phase III Trial
Combination of Baricitinib and Anti-TNF vs. Baricitinib in Patients With Rheumatoid Arthritis: a Randomized Controlled Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, Adalimumab
Study Phase: Phase 3
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Phase: Phase 4
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
JAKINIB Study: 'Observational', Multicentre Trial Collecting Prospective and On-going Clinical and Laboratory Data for Patients Treated With JAK Inhibitors for Inflammatory Rheumatism According to EMA.
JAKINIB Study: 'Observational', Multicentre Trial Collecting Prospective and On-going Clinical and Laboratory Data for Patients Treated With JAK Inhibitors for Inflammatory Rheumatism According to EMA.
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Other
BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)
BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)
Enrollment Status: Terminated
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: Baricitinib Oral Tablet [Olumiant]
Study Phase: Phase 4
Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept
Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept
Enrollment Status: Completed
Publish Date: January 03, 2022
Intervention Type: Biological, Drug
Study Phase: Not Applicable
Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach
Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Drug: IL-2
Study Phase: Phase 2
Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)
Assessment of the Clinical and Medico-economic Impact of SinnoTest®, a Software That Predicts the Effectiveness of Biotherapy Treatments, in Patients With Rheumatoid Arthritis (RA)
Enrollment Status: Withdrawn
Publish Date: May 03, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Not Applicable
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

326 Total Publications

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.
Journal: Annals of the rheumatic diseases
Published: November 21, 2025

Frequently Asked Questions about Bruno J. Fautrel

Is Bruno J. Fautrel a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Bruno J. Fautrel is classified as an Elite expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bruno J. Fautrel participate in research or clinical trials?

Yes. Bruno J. Fautrel has published 326 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Bruno J. Fautrel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fautrel's expertise for a condition
ConditionClose
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile